CancerNetwork Members: Login | Register
 
CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
PATIENTS
NURSES
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

Oncology NEWS International. Vol. 18 No. 5
Letter to the Editor 

Prostate ca survivor values regular PSA screening
Readers respond to “Two major studies add fuel to fire of PSA controversy,” April 2009, Cancer Care Practice & Policy, page 8.

By Stan Brody | May 21, 2009

As a prostate cancer survivor whose primary care physician missed my cancer for the better part of six years, I object to the position that PSA doesn’t matter.

Like the vast majority of men, I was “stupid” where my healthcare was concerned. I never asked for a copy of my blood work or questioned the results of my tests. After all, we treat our doctors like gods.

After I was diagnosed, and endured the usual battle with my insurance carrier over the issue of a pre-existing condition, I retrieved years’ worth of blood work results—and there it was staring me in the face. My PSA had been steadily increasing over several years. The results showed that my testosterone levels had been low; consequently my doctor was routinely giving me hormone injections.

Successful medical care is a partnership between patient and doctor. Had I obtained my blood tests sooner and asked why certain numbers had changed, then perhaps my doctor might have caught my cancer earlier. But most primary care physicians do not fully understand how to use PSA testing and wind up ordering biopsies, afraid of the attorney waiting in the wings.

Thomas Stamey, MD, considered to be the father of PSA testing, said that it is not the results of a single test but the trend of those results that is critical. The secret to the successful treatment of any cancer is early diagnosis. PSA testing is merely a tool, and when paired with a digital rectal exam, it can support a wait-and-watch approach so that biopsies or other tests are ordered only when warranted.

There is no valid reason to eliminate PSA screening as part of the general blood work-up during a routine physical exam. PSA screen can be done at a nominal cost. I would hope that a physician would place more value on a man’s life than on the cost of a test.

 

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

  • Bladder Cancer
  • Bone Metastases
  • Breast Cancer
  • CML
  • Colorectal Cancer
  • End-of-Life
  • GIST
  • Genetics Genomics
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Integrative Oncology
  • Leukemia
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Nausea & Vomiting
  • Palliative Care
  • Pancreatic Cancer
  • Practice Management
  • Practice & Policy
  • Prostate Cancer
  • RCC
  • Skin Cancer
  • Triple-Negative Breast
  • Testicular Cancer


More Topics 

 
PUBLICATIONS
ONCOLOGY Journal ONCOLOGY Nurse Edition Journal Cancer Management: A Multidisciplinary Approach

ONCOLOGY:
Perspectives on Best Practices

ONCOLOGY:
Nurse Edition

CANCER
MANAGEMENT
:
A Multidisciplinary
Approach


 
IMAGE IQ

This patient is at increased risk for which type of neoplasia?

A 28-year-old, slightly obese Caucasian woman presented with a long-standing history of intermittently painful “bumps” on both shoulders and her upper back.

 

More Image IQs:

 

 
FROM PHYSICIANS PRACTICE
Tax Schemes Every Physician Should Avoid
Ike Devji, JD, January 31, 2012
The next 60 days marks the final push to sell physicians across the United States tax plans of both good and questionable value.
Boosting Collections at Your Medical Practice: Whose Job Is It?
P.J. Cloud-Moulds, January 28, 2012
Embrace the relationship between your billing company and your medical practice staff.
Managing Difficult Medical Practice Employees
Shelly K. Schwartz, January 27, 2012
Tips for transforming immature staff members into great employees.
Prevent Physician Distraction When Using mHealth Technology
Aubrey Westgate, January 25, 2012
As more and more physicians use handheld mobile technology in their day-to-day work, some critics are raising concerns about “distracted doctoring.”
Can That Applicant Do the Job at Your Medical Practice?
Karen Zupko, January 25, 2012
If like many communities, yours has significant numbers of non-English speaking people with whom neither you nor your staff are able to converse, your practice is at a serious disadvantage.
 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Head and Neck Tumors
  • 46-Year-Old Woman Presents With Difficulty in Ambulation, and Swelling and Discoloration of Both Eyelids
  • Optimizing Outcomes of Advanced Prostate Cancer: Drug Sequencing and Novel Therapeutic Approaches
  • A 28-Year-Old Woman Presents With a Long-Standing History of Intermittently Painful “Bumps” on Both Her Shoulders and Upper Back
  • Controversies in Oncologist-Patient Communication: A Nuanced Approach to Autonomy, Culture, and Paternalism
  • Evolution of Treatment Options for Patients With CRPC and Bone Metastases: Bone-Targeted Agents That Go Beyond Palliation of Symptoms to Improve Overall Survival
  • Ending the Shortage of Generic Oncology Drugs
  • Processed and Red Meat Consumption Linked to Slight Increase in Risk of Pancreatic Cancer
  • New Mutation May Act as Driver in Subset of Lung Cancer Patients
  • Could Aspirin Be a Viable Adjuvant Treatment for Cancer?
  • Advances and New Research in the Treatment of Kidney Cancer
  • New Way to Predict Prostate Cancer Severity—Size of Prostate
  • Vismodegib Granted FDA Approval for Treatment of Basal Cell Carcinoma
  • FDA Grants Approval to Axitinib for the Treatment of Advanced Renal Cell Carcinoma
  • Why BRAF-Mutated Colorectal Cancers Don't Respond to BRAF Inhibitors
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • When to Treat Myelodysplastic Syndromes
  • Are We Ready for Neoadjuvant Therapy in Potentially Resectable Pancreatic Cancer?
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • PSA Screening for Prostate Cancer Put Into Question By the U.S. Preventive Services Task Force
  • When to Treat Myelodysplastic Syndromes
  • ASCO 2011: A Paradigm Shift in the Treatment of Endometrial Cancer
  • Are We Ready for Neoadjuvant Therapy in Potentially Resectable Pancreatic Cancer?
  • Evolving Therapeutic Paradigms for Advanced Prostate Cancer
Click here to subscribe to our newsletter
 
JOB LISTINGS

Post a job

Powered by SearchMedica Jobs



CancerNetwork on Facebook

 

CancerNetwork | CME LLC | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2012 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy